INO Strangle Strategy
INO (Inovio Pharmaceuticals, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis.
INO (Inovio Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $58.9M, a beta of 1.47 versus the broader market, a 52-week range of 1.03-2.98, average daily share volume of 2.8M, a public-listing history dating back to 1998, approximately 134 full-time employees. These structural characteristics shape how INO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.47 indicates INO has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on INO?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current INO snapshot
As of June 30, 2026, spot at $1.10, ATM IV 191.00%, IV rank 37.43%, expected move 54.76%. The strangle on INO below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 31-day expiry.
Why this strangle structure on INO specifically: INO IV at 191.00% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 54.76% (roughly $0.60 on the underlying). The 31-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated INO expiries trade a higher absolute premium for lower per-day decay. Position sizing on INO should anchor to the underlying notional of $1.10 per share and to the trader's directional view on INO stock.
INO strangle setup
The INO strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With INO near $1.10, the first option leg uses a $1.16 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed INO chain at a 31-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 INO shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $1.16 | N/A |
| Buy 1 | Put | $1.05 | N/A |
INO strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
INO strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on INO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on INO
Strangles on INO are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the INO chain.
INO thesis for this strangle
The market-implied 1-standard-deviation range for INO extends from approximately $0.50 on the downside to $1.70 on the upside. A INO long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current INO IV rank near 37.43% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on INO should anchor more to the directional view and the expected-move geometry. As a Healthcare name, INO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to INO-specific events.
INO strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. INO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move INO alongside the broader basket even when INO-specific fundamentals are unchanged. Always rebuild the position from current INO chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on INO?
- A strangle on INO is the strangle strategy applied to INO (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With INO stock trading near $1.10, the strikes shown on this page are snapped to the nearest listed INO chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are INO strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the INO strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 191.00%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a INO strangle?
- The breakeven for the INO strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current INO market-implied 1-standard-deviation expected move is approximately 54.76%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on INO?
- Strangles on INO are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the INO chain.
- How does current INO implied volatility affect this strangle?
- INO ATM IV is at 191.00% with IV rank near 37.43%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.